公开(公告)号：US11851388B2

公开(公告)日：2023-12-26

申请号：US17476101

申请日：2021-09-15

申请人： FMC AGRO SINGAPORE PTE. LTD.

发明人： Paolo Bellandi ,  Giampaolo Zanardi ,  Ravindra Vitthal Datar ,  Chockalingam Devarajan ,  Swamynathan Murali ,  Narayana Swamy

IPC分类号： C07D211/60 ,  C07D215/18 ,  C07C209/70 ,  C07C231/02 ,  C07C231/08 ,  C07C231/14 ,  C07C209/62

CPC分类号： C07C209/62 ,  C07C209/70 ,  C07C231/02 ,  C07C231/08 ,  C07C231/14 ,  C07D211/60 ,  C07D215/18 ,  C07C2602/08

摘要： A compound of Formula (IX):

公开(公告)号：US20220305144A1

公开(公告)日：2022-09-29

申请号：US17722628

申请日：2022-04-18

申请人： Bristol-Myers Squibb Company

发明人： David J. Donnelly ,  Erin Lee Cole ,  Richard Charles Burrell ,  Wesley A. Turley ,  Alban J. Allentoff ,  Michael Arthur Wallace ,  James Aaron Balog ,  Audris Huang ,  Mette Skinbjerg

IPC分类号： A61K51/04 ,  C07B59/00 ,  C07D215/18 ,  G01N33/60

摘要： The present invention relates to radiolabeled IDO1 inhibitors or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of IDO enzymes in mammals.

公开(公告)号：US20220267273A1

公开(公告)日：2022-08-25

申请号：US17552929

申请日：2021-12-16

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Albert J. DELMONTE ,  Benjamin M. COHEN ,  Kenneth Joseph FRAUNHOFFER ,  Sergei KOLOTUCHIN ,  Francisco GONZALEZ-BOBES ,  Gregory Louis BEUTNER ,  Adam Joseph FREITAG ,  Michael Scott BULTMAN ,  Yu FAN ,  Prantik MAITY ,  Ian Scott YOUNG ,  Hilary Plake BECK ,  Maksim OSIPOV ,  Jay Patrick POWERS ,  Maureen Kay REILLY ,  Hunter Paul SHUNATONA ,  James Ross WALKER ,  Mikhail ZIBINSKY

IPC分类号： C07D215/18 ,  C07C67/343 ,  C07C51/09 ,  C07C67/333

摘要： The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.

公开(公告)号：US20220127233A1

公开(公告)日：2022-04-28

申请号：US17524789

申请日：2021-11-12

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Albert J. DELMONTE ,  Benjamin M. COHEN ,  Kenneth Joseph FRAUNHOFFER ,  Sergei KOLOTUCHIN ,  Francisco GONZALEZ-BOBES ,  Gregory Louis BEUTNER ,  Adam Joseph FREITAG ,  Michael Scott BULTMAN ,  Yu FAN ,  Prantik MAITY ,  Ian Scott YOUNG ,  Hilary Plake BECK ,  Maksim OSIPOV ,  Jay Patrick POWERS ,  Maureen Kay REILLY ,  Hunter Paul SHUNATONA ,  James Ross WALKER ,  Mikhail ZIBINSKY

IPC分类号： C07D215/18 ,  C07C67/343 ,  C07C51/09 ,  C07C67/333

摘要： The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.

公开(公告)号：US11236050B2

公开(公告)日：2022-02-01

申请号：US16771096

申请日：2018-12-08

申请人： MSN LABORATORIES PRIVATE LIMITED, R&D CENTER ,  Thirumalai Rajan Srinivasan

发明人： Thirumalai Rajan Srinivasan ,  Eswaraiah Sajja ,  Venkata Panakala Rao Gogulapati ,  Rajeshwar Reddy Sagyam ,  Pavan Kumar Reddy Bandla ,  Srinivasulu Rangineni

IPC分类号： C07D215/18 ,  C07D215/48

摘要： The present invention relates to novel polymorphs of 4-[3-chloro-4-(N′-cyclopropyl ureido) phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate represented by following structural formula-1a and process for preparation thereof. Further, the present invention relates to an improved process for the preparation of 4-[3-chloro-4-(N′-cyclopropylureido) phenoxy]-7-methoxyquinoline-6-carboxamide compound of formula-1 or its salts and its intermediates thereof.

公开(公告)号：US20210179621A1

公开(公告)日：2021-06-17

申请号：US16760815

申请日：2018-10-30

申请人： The Regents of the University of Colorado, a body corporale

发明人： Hang Hubert Yin ,  Shuting Zhang ,  Zhenyi Hu

IPC分类号： C07D487/04 ,  C07D215/18 ,  C07D215/20 ,  C07D401/04

摘要： Toll-like receptor 8 (TLR8)-specific inhibitors and methods of using the same in individuals having an autoimmune disease or an inflammatory disorder.

公开(公告)号：US20210053927A1

公开(公告)日：2021-02-25

申请号：US16326453

申请日：2017-08-18

申请人： University College Dublin

发明人： Patrick Guiry ,  Catherine Godson

IPC分类号： C07D241/42 ,  C07D215/14 ,  C07D215/18 ,  C07D405/06 ,  C07D217/22 ,  C07D263/34 ,  C07D263/32 ,  C07D413/06 ,  C07D233/68 ,  C07D407/06 ,  C07D307/80 ,  C07D333/56 ,  C07D409/06

摘要： The present invention relates to a compound of formula (I): wherein L is an optionally substituted heterocyclic group excluding unsubstituted monocyclic pyridine groups; wherein a is 0, 1 or 2; wherein R1 is H or with R2 is a bond; wherein R2 is an optionally substituted alkoxy or aryloxy group, or with R1 forms a bond; wherein R3 is an optionally substituted alkyl group; and wherein R4 is CH2, CMe2 or O. Such compounds may be used in the treatment or prophylaxis of a disease or condition in which inhibition of acute inflammation and/or promotion of its resolution and/or suppression of fibrosis.

公开(公告)号：US20210002256A1

公开(公告)日：2021-01-07

申请号：US16948467

申请日：2020-09-21

申请人： Merck Patent GmbH

发明人： Brian A. Sherer ,  Xiaoling Chen ,  Esther Cleary ,  Nadia Brugger

IPC分类号： C07D401/14 ,  C07D215/18 ,  C07D413/04 ,  C07D401/12 ,  A61K31/4709 ,  C07D215/12 ,  C07D215/14 ,  C07D241/42 ,  C07D401/04 ,  C07D413/14 ,  C07D451/02 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04

摘要： A compound of Formula I or pharmaceutically acceptable compositions thereof, is useful to as a TLR7/8 antagonist.

公开(公告)号：US10428054B2

公开(公告)日：2019-10-01

申请号：US15851434

申请日：2017-12-21

申请人： CHDI Foundation, Inc.

发明人： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  William Mitchell ,  Naomi Went

IPC分类号： A61K31/517 ,  A61K31/495 ,  A61K31/47 ,  A61K31/425 ,  A61K31/42 ,  A61K31/415 ,  A61K31/34 ,  C07D413/12 ,  C07D215/18 ,  C07D319/18 ,  C07D333/06 ,  C07D241/42 ,  C07D277/24 ,  C07D277/64 ,  C07D213/46 ,  C07D307/79 ,  C07D209/08 ,  C07D217/02 ,  C07D231/56 ,  C07D235/08 ,  C07D237/28 ,  C07D239/74 ,  C07D261/20 ,  C07D263/56 ,  C07D333/10 ,  C07D333/28 ,  C07D407/12 ,  A61K31/428 ,  A61K31/416 ,  A61K31/343 ,  A61K31/423 ,  A61K31/4184 ,  A61K31/502

摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US20190248746A1

公开(公告)日：2019-08-15

申请号：US16391537

申请日：2019-04-23

申请人： Guangdong Moltech Pharma Co. Ltd

发明人： Yingjie LAI

IPC分类号： C07D215/18 ,  A61P11/06 ,  A61K31/47

CPC分类号： C07D215/18 ,  A61K31/47 ,  A61P11/06

摘要： A cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and applications thereof, wherein the structural formula of the compound is as follows: An application of the compound or its pharmaceutically acceptable salts, hydrates, solvates, or prodrugs in preparing a drug for treating and/or preventing and/or delaying and/or providing adjuvant therapy for asthma and/or allergic rhinitis and asthma syndromes is provided. A drug composition includes the cyclopropyl unsaturated quinoline compound or the pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof. The compound series has favorable foreground in preparing drugs for treating and/or preventing and/or delaying and/or providing adjuvant therapy for asthma and/or allergic rhinitis and asthma syndromes.